More New Yorkers received scripts for buprenorphine, a med used to treat opioid addiction, amid fight against record-high ...

Distribution of prescribed opioid analgesics is lower in majority non-White versus majority White communities across all levels of socioeconomic deprivation.

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.